Going public is a transformative event for a life sciences company; it is complex, requires significant attention for executive management, involves the entire organization and carries high execution risk. Whether you go public via a direct listing initial public offering, a special purpose acquisition company, or other reverse merger, the level of effort and the cost of preparation should not be underestimated. Beginning preparation early enables an organization to better manage both.
We explore this topic and more in our on-demand webcast. Whether you’re a biopharma, medtech or other life sciences organization, watch to learn about the latest trends in the public markets as well as the steps you must take now for IPO readiness.